Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21149918rdf:typepubmed:Citationlld:pubmed
pubmed-article:21149918lifeskim:mentionsumls-concept:C0019682lld:lifeskim
pubmed-article:21149918lifeskim:mentionsumls-concept:C0019699lld:lifeskim
pubmed-article:21149918lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:21149918lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:21149918lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:21149918lifeskim:mentionsumls-concept:C0209738lld:lifeskim
pubmed-article:21149918lifeskim:mentionsumls-concept:C0663655lld:lifeskim
pubmed-article:21149918lifeskim:mentionsumls-concept:C0814633lld:lifeskim
pubmed-article:21149918pubmed:issue8lld:pubmed
pubmed-article:21149918pubmed:dateCreated2010-12-14lld:pubmed
pubmed-article:21149918pubmed:abstractTextNo data on once-daily dosing of nucleoside analogues in African children currently exist. We compared the pharmacokinetics (PK) of once- versus twice-daily lamivudine and abacavir treatment using the World Health Organization recommended weight band dosing of scored adult tablets.lld:pubmed
pubmed-article:21149918pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21149918pubmed:languageenglld:pubmed
pubmed-article:21149918pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21149918pubmed:citationSubsetIMlld:pubmed
pubmed-article:21149918pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21149918pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21149918pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21149918pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21149918pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21149918pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21149918pubmed:statusMEDLINElld:pubmed
pubmed-article:21149918pubmed:issn2040-2058lld:pubmed
pubmed-article:21149918pubmed:authorpubmed-author:MugyenyiPeter...lld:pubmed
pubmed-article:21149918pubmed:authorpubmed-author:GibbDiana MDMlld:pubmed
pubmed-article:21149918pubmed:authorpubmed-author:MusokePhilipp...lld:pubmed
pubmed-article:21149918pubmed:authorpubmed-author:WalkerA...lld:pubmed
pubmed-article:21149918pubmed:authorpubmed-author:BurgerDavidDlld:pubmed
pubmed-article:21149918pubmed:authorpubmed-author:Bakeera-Kitak...lld:pubmed
pubmed-article:21149918pubmed:authorpubmed-author:AdkisonKimber...lld:pubmed
pubmed-article:21149918pubmed:authorpubmed-author:KekitiinwaAde...lld:pubmed
pubmed-article:21149918pubmed:authorpubmed-author:MusiimeVictor...lld:pubmed
pubmed-article:21149918pubmed:authorpubmed-author:ThomasonMarga...lld:pubmed
pubmed-article:21149918pubmed:authorpubmed-author:SnowdenWendy...lld:pubmed
pubmed-article:21149918pubmed:authorpubmed-author:KendallLindsa...lld:pubmed
pubmed-article:21149918pubmed:authorpubmed-author:OdongoFlorenc...lld:pubmed
pubmed-article:21149918pubmed:authorpubmed-author:ARROW Trial...lld:pubmed
pubmed-article:21149918pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21149918pubmed:volume15lld:pubmed
pubmed-article:21149918pubmed:ownerNLMlld:pubmed
pubmed-article:21149918pubmed:authorsCompleteYlld:pubmed
pubmed-article:21149918pubmed:pagination1115-24lld:pubmed
pubmed-article:21149918pubmed:meshHeadingpubmed-meshheading:21149918...lld:pubmed
pubmed-article:21149918pubmed:meshHeadingpubmed-meshheading:21149918...lld:pubmed
pubmed-article:21149918pubmed:meshHeadingpubmed-meshheading:21149918...lld:pubmed
pubmed-article:21149918pubmed:meshHeadingpubmed-meshheading:21149918...lld:pubmed
pubmed-article:21149918pubmed:meshHeadingpubmed-meshheading:21149918...lld:pubmed
pubmed-article:21149918pubmed:meshHeadingpubmed-meshheading:21149918...lld:pubmed
pubmed-article:21149918pubmed:meshHeadingpubmed-meshheading:21149918...lld:pubmed
pubmed-article:21149918pubmed:meshHeadingpubmed-meshheading:21149918...lld:pubmed
pubmed-article:21149918pubmed:meshHeadingpubmed-meshheading:21149918...lld:pubmed
pubmed-article:21149918pubmed:meshHeadingpubmed-meshheading:21149918...lld:pubmed
pubmed-article:21149918pubmed:meshHeadingpubmed-meshheading:21149918...lld:pubmed
pubmed-article:21149918pubmed:meshHeadingpubmed-meshheading:21149918...lld:pubmed
pubmed-article:21149918pubmed:meshHeadingpubmed-meshheading:21149918...lld:pubmed
pubmed-article:21149918pubmed:meshHeadingpubmed-meshheading:21149918...lld:pubmed
pubmed-article:21149918pubmed:meshHeadingpubmed-meshheading:21149918...lld:pubmed
pubmed-article:21149918pubmed:year2010lld:pubmed
pubmed-article:21149918pubmed:articleTitlePharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.lld:pubmed
pubmed-article:21149918pubmed:affiliationJoint Clinical Research Centre, Kampala, Uganda.lld:pubmed
pubmed-article:21149918pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21149918pubmed:publicationTypeControlled Clinical Triallld:pubmed
pubmed-article:21149918pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:21149918pubmed:publicationTypeMulticenter Studylld:pubmed